All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Adjuvant CDK4/6 Inhibitors Lay a Solid Treatment Foundation in HR+, HER2– Breast Cancer

March 19th 2025

Tanya Gupta, MD, highlights the utility of adjuvant CDK4/6 and PARP inhibitors in patients with HR-positive, HER2-negative breast cancer.

HLX22 Receives FDA Orphan Drug Designation in Gastric Cancer

March 19th 2025

The FDA has granted orphan drug designation to HLX22 for the treatment of patients with gastric cancer based on positive data from the HLX22-GC-201 study.

Fruquintinib/Sintilimab Generates Favorable PFS Outcomes in Advanced RCC

March 19th 2025

Second-line fruquintinib plus sintilimab improved PFS, ORR, and DOR outcomes vs everolimus or axitinib monotherapy in advanced/metastatic RCC.

Immunotherapy May Boost KRAS-Targeted Therapy in Pancreatic Cancer

March 19th 2025

A preclinical study offers a foundation for a combination strategy in future clinical trials for KRAS mutations.

Association Between CLDN18 and MUC1 Could Drive Novel Targeted Therapy Options in GI Cancers

March 19th 2025

Aditya Shreenivas, MD, MS, discusses the association between Claudin 18 and MUC1 biomarkers and ongoing targeted therapy challenges.

CA19-9 Plus Liquid Biopsy Represents Diagnostic Biomarker of Interest for Early-Stage Pancreatic Cancer Detection

March 19th 2025

Ajay Goel, PhD, AGAF, discusses the potential utility of CA19-9 with an exosome-based liquid biopsy as a diagnostic biomarker in early-stage pancreatic cancer.

Ocular AEs From Mirvetuximab Soravtansine Do Not Impact HRQOL in FRα+ Platinum-Resistant Ovarian Cancer

March 18th 2025

Ocular adverse effects stemming from mirvetuximab soravtansine did not significantly affect HRQOL in FRα-positive platinum-resistant ovarian cancer.

HER2DX Affects Approximately 50% of Treatment Decisions for HER2+ Breast Cancer

March 18th 2025

HER2DX aided in HER2+ breast cancer therapy decisions and the pCR rate was comparable among those who did and did not have HER2DX-driven treatment changes.

QuANTUM-Wild Trial to Explore Correlative Outcomes With Quizartinib in FLT3-Negative AML

March 18th 2025

David M. Swoboda, MD, discusses data with quizartinib in FLT3-negative AML from the QUIWI trial and the rationale for the QuANTUM-Wild trial.

Viral Mimicry May Enhance Immune Response Against Glioblastomas

March 18th 2025

Scientists from Sylvester Comprehensive Cancer Center have found that targeting ZNF638 can induce an antiviral response in glioblastoma.

Penpulimab Gains NMPA Approval for First-Line Treatment of Recurrent or Metastatic NPC

March 18th 2025

Penpulimab received NMPA approval for first-line use with chemotherapy in recurrent or metastatic nasopharyngeal carcinoma.

FDA Grants Orphan Drug Designation to Bexobrutideg in Waldenström Macroglobulinemia

March 18th 2025

Bexobrutideg received orphan drug designation from the FDA for the treatment of patients with Waldenström macroglobulinemia.

Minimally Invasive Surgical Approaches Are a Convenient and Effective CRC Management Option

March 18th 2025

Andreas M. Kaiser, MD, discusses the differences between minimally invasive surgical approaches for colorectal cancer in community vs academic settings.

Abemaciclib/Hormonal Therapy Combo Yields Clinical Activity in LGSOC/EEC

March 18th 2025

Treatment with abemaciclib plus hormonal therapy showed promise in LGSOC/EEC but not in HGSOC, and larger studies are needed to validate these findings.

Nadofaragene Firadenovec Is Effective With Beneficial Dosing Schedule in Real-World for BCG-Unresponsive NMIBC

March 18th 2025

Mark Tyson II, MD, MPH, and Jacob Moyer, BS, detail findings from the first real-world study of nadofaragene firadenovec in BCG-unresponsive NMIBC.

Off-the-Shelf CAR T-Cell Therapy P-BCMA-ALLO1 Is Efficacious in Relapsed/Refractory Multiple Myeloma

March 18th 2025

P-BCMA-ALLO1 displayed high response rates and compelling safety in a heavily pretreated population of patients with relapsed/refractory multiple myeloma.

Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer

March 17th 2025

The median DOR with Rina-S was not reached and the treatment was well tolerated in patients with FRα-unselected platinum-resistant ovarian cancer.

Maintenance Selinexor Extends PFS in TP53 Wild-Type Endometrial Cancer

March 17th 2025

Maintenance selinexor improved progression-free survival in TP53 wild-type advanced endometrial cancer.

Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer

March 17th 2025

Pamiparib plus surufatinib showed signals of activity with a largely hematologic adverse effect profile in patients with PARP-pretreated, platinum-resistant ovarian cancer.

Avutometinib/Defactinib Combo Drives Responses in Recurrent Low-Grade Serous Ovarian Cancer

March 17th 2025

The combination of avutometinib and defactinib produced durable responses in recurrent low-grade serous ovarian cancer.